---

$2.92

+0.1240 ( +4.43% ) 185.3K

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2023-10-10	Sale	-20000.00	Tregoning Kathleen
2023-10-10	Sale	-20000.00	Deshpande Milind
2023-10-10	Sale	-20000.00	THOMAS FRANK E
2023-10-10	Sale	-20000.00	Smith Cynthia
2023-10-10	Sale	-20000.00	Pottage John C Jr
2023-09-15	Sale	-39496.00	HAMED KAMAL
2023-08-30	Sale	-1854.00	Keutzer Timothy
2023-08-30	Sale	-1854.00	JOSEPH TAMARA L
2023-08-30	Sale	-9040.00	Mahadevia Ankit
2023-08-30	Sale	-1854.00	Shukla Sath